

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Single Technology Appraisal

#### Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma ID1609

#### Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Bristol-Myers Squibb (nivolumab, ipilimumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Asbestos Victims Support Groups Forum UK</li> <li>• Black Health Agency</li> <li>• British Lung Foundation</li> <li>• Cancer 52</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• Mesothelioma UK</li> <li>• Muslim Council of Britain</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• Association of Respiratory Nurse Specialists</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• British Thoracic Oncology Group</li> <li>• British Thoracic Society</li> <li>• Cancer Research UK</li> <li>• Lung Cancer Nursing UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• GMB - Britain's General Union</li> <li>• Health and Safety Executive</li> <li>• Healthcare Improvement Scotland</li> <li>• Joint Union Asbestos Committee</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Trades Union Congress</li> <li>• UK Asbestos Training Association</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• A A H Pharmaceuticals (cisplatin)</li> <li>• Accord (carboplatin, cisplatin)</li> <li>• Consilient Health (carboplatin)</li> <li>• Dr Reddy's Laboratories (pemetrexed)</li> <li>• Eli Lilly and Company (pemetrexed)</li> <li>• Fresenius Kabi Oncology (carboplatin, pemetrexed)</li> <li>• Pfizer (carboplatin, cisplatin, raltitrexed)</li> <li>• Sandoz (cisplatin)</li> </ul>

Final stakeholder list for the technology appraisal of nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma ID1609

Issue date: September 2020

© National Institute for Health and Care Excellence 2020. All rights reserved.

Page 1 of 3

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Health Forum</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Newark &amp; Sherwood CCG</li> <li>• NHS West Leicestershire CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Seacross Pharmaceuticals (pemetrexed)</li> <li>• Teva UK (carboplatin, cisplatin)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Bart's Mesothelioma Research</li> <li>• Cochrane Lung Cancer Group</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• June Hancock Mesothelioma Research Fund</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.